Analysts are saying the future for biosimilars may be in doubt. It’s not time to give up on biosimilars, however. It would appear that a persistent problem in the U.S. is that conditions conducive to a competitive market haven’t been established.
Biosimilars Continue To Exhibit Market Failure
